List view / Grid view
11 May 2018 | By European Pharmaceutical Review
A new study found that infections caused by the drug resistant bacteria - methicillin-resistant Staphylococcus aureus, known as MRSA - are no more expensive to treat than MSSA, the methicillin-susceptible version of the same bacteria.
6 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Adding the targeted cancer therapy drug crizotinib to radiation therapy for tumours associated with the genetic disorder neurofibromatosis 2 may reduce the hearing damage that can be exacerbated by radiotherapy...
2 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A topical gel made from a class of common blood pressure medications has been found to accelerate the healing process of chronic skin wounds...
13 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have developed a way to successfully deliver nano-sized, platinum-based chemotherapy drugs to treat a form of bladder cancer...
24 June 2016 | By Victoria White, Digital Content Producer
Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases...
7 February 2009 | By
During the optimisation of drug candidates, improvements in affinity and selectivity play a critical role. This task is usually accomplished by establishing accurate correlations between the affinity/selectivity of different chemical scaffolds and through chemical modifications to a selected scaffold.
21 September 2007 | By Dr Ernesto Freire, Faculty Professor, Johns Hopkins University, Baltimore
Drug development involves the identification and subsequent optimisation of low molecular weight compounds with a desired biological activity. Often, the initial binding affinity of those compounds towards their intended target needs to be improved by five or more orders of magnitude before they become viable drug candidates; a process that…
Send this to a friend
Follow: